drugset / Trial / NCT04142788
RELieving Increasing oEdema Due to Heart Failure
RandomizedParallel-groupSingle-blindTreatment
Summary
This trial will investigate the potential for patiromer-facilitated use of higher doses of mineralocorticoid antagonists in addition to standard care (compared to standard care alone) to improve congestion, well-being and mortality in people who have worsening congestion due to heart failure and hyperkalaemia.
Timeline
- Start
- 2020-08-26
- Primary completion
- 2022-12-20
- Completion
- 2022-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eplerenone | Unknown | 50 mg | — |
| Subject | Patiromer | Other / unclassified | 8.4 g | — |
| Subject | Patiromer | Other / unclassified | 25.2 g | — |
| Subject | Spironolactone | Small molecule | 200 mg | — |